EUVIMEDPoznaj EUVIMED
Crossref

DNA ‐hypermethylated human gastric cancer circumvents apoptosis in the absence of TP53 mutation

Yasunobu Mano iD, Keisuke Matsusaka, Motoaki Seki iD, Kazuko Kita, Masaki Fukuyo, Bahityar Rahmutulla, Genki Usui, Ryoji Fujiki, Masayuki Urabe, Hiroyuki Abe, Hisahiro Matsubara, Tetsuo Ushiku and 3 more

The Journal of Pathology · 2025-12 · 267 (4) · 435-449

DOI: 10.1002/path.6480 ↗

At a glance

Journal article in The Journal of Pathology, published online on 2025-10-09. Written by Yasunobu Mano and 14 co-authors. Institution: Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan. Major MEDLINE topics: Stomach Neoplasms, Apoptosis, Tumor Suppressor Protein p53, DNA Methylation. Cited 3 times so far (Crossref); 50 references. Funded by: Japan Agency for Medical Research and Development, Chiba University, Japan Society for the Promotion of Science.

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

p53 is one of the most important tumour suppressors exerting antitumour effects primarily via apoptosis. TP53 mutations are common in gastric tumorigenesis; however, nearly half of the gastric cancers (GCs) remain wildtype TP53 ( TP53 _WT). We investigated epigenetic/genetic profiles of GCs and the carcinogenic mechanisms underlying GCs with TP53 _WT. Comprehensive DNA methylation analysis revealed four DNA methylation epigenotypes (MEs) in GCs, namely, high ME (HME), extremely HME (E‐HME), low ME (LME), and extremely LME (E‐LME). E‐HME matched Epstein–Barr virus (EBV)‐positive GC (E‐HME/EBV). HME can be further categorised into MLH1‐deficient (HME_MLH1(−)) and ‐proficient cases. The Cancer Genome Atlas data confirmed that HME_MLH1(−)/microsatellite instability (MSI) and E‐HME/EBV cases significantly retained TP53 _WT and had higher MDM2 expression levels than other MEs. We hypothesised that apoptosis pathways in TP53 _WT GC may be suppressed post‐transcriptionally by activated MDM2. Short hairpin RNA‐mediated MDM2 knockdown and the p53‐MDM2 inhibitors, nutlin‐3 and RG7388, induced apoptosis in TP53 _WT GC cells, indicating that activated MDM2 suppressed p53 protein levels and thereby attenuated the downstream p53 pathway activation, which was restored upon MDM2 knockdown or inhibitor treatment. Collectively, DNA‐hypermethylated GC cases, HME_MLH1(−)/MSI and E‐HME/EBV, follow a unique carcinogenic pathway to evade apoptosis in the absence of TP53 mutation, potentially making them responsive to therapeutic strategies that function primarily through the p53 pathway. © 2025 The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Stomach NeoplasmsApoptosisTumor Suppressor Protein p53DNA MethylationMutationHumansProto-Oncogene Proteins c-mdm2MutL Protein Homolog 1Cell Line, TumorGene Expression Regulation, NeoplasticEpigenesis, GeneticMicrosatellite Instability

Author keywords

DNA methylation epigenotypeEpstein–Barr virusMDM2apoptosisgastric cancermicrosatellite instabilityp53

Substances

Tumor Suppressor Protein p53TP53 protein, humanProto-Oncogene Proteins c-mdm2MutL Protein Homolog 1MDM2 protein, humanMLH1 protein, human

Authors and institutions

  • Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Department of Diagnostic Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Department of Genome Research and Development, Kazusa DNA Research Institute, Chiba, Japan.
  • Department of Pathology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.
  • Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.
  • Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

ORCID profiles: Yasunobu Mano, Motoaki Seki, Atsushi Kaneda

Funding

  • Japan Agency for Medical Research and Development
  • Chiba University
  • Japan Society for the Promotion of Science

Cite

APA

Mano, Y., Matsusaka, K., Seki, M., Kita, K., Fukuyo, M., Rahmutulla, B., Usui, G., Fujiki, R., Urabe, M., Abe, H., Matsubara, H., Ushiku, T., Seto, Y., Fukayama, M., & Kaneda, A. (2025). DNA ‐hypermethylated human gastric cancer circumvents apoptosis in the absence of TP53 mutation. The Journal of Pathology, 267(4), 435-449. https://doi.org/10.1002/path.6480

Vancouver

Mano Y, Matsusaka K, Seki M, Kita K, Fukuyo M, Rahmutulla B, et al. DNA ‐hypermethylated human gastric cancer circumvents apoptosis in the absence of TP53 mutation. The Journal of Pathology. 2025;267(4):435-449. doi:10.1002/path.6480

BibTeX
@article{Mano2025,
  author = {Mano, Yasunobu and Matsusaka, Keisuke and Seki, Motoaki and Kita, Kazuko and Fukuyo, Masaki and Rahmutulla, Bahityar and Usui, Genki and Fujiki, Ryoji and Urabe, Masayuki and Abe, Hiroyuki and Matsubara, Hisahiro and Ushiku, Tetsuo and Seto, Yasuyuki and Fukayama, Masashi and Kaneda, Atsushi},
  title = {DNA ‐hypermethylated human gastric cancer circumvents apoptosis in the absence of TP53 mutation},
  journal = {The Journal of Pathology},
  year = {2025},
  volume = {267},
  number = {4},
  pages = {435--449},
  doi = {10.1002/path.6480}
}
Start for free →